Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety

You may be eligible if

• PROTOCOL ENTRY CRITERIA:
• -Disease Characteristics--
• Primary diagnosis of generalized anxiety or panic disorder Determined by Structured Clinical Interview for DSM IV
• Hamilton Anxiety Scale (HAM-A) score at least 14 AND Profile of Mood States (POMS) tension/anxiety scale score at least 20
• Concurrent diagnoses allowed: Mild to moderate agoraphobia Simple or social phobias Secondary unipolar affective disorders
• No current substance abuse, dependence, or substance abuse treatment Drug-free urine sample required
• No history of other primary Axis I diagnosis other than tobacco dependence
• -Prior/Concurrent Therapy--
• No prior formalized non-drug therapy for anxiety disorder
• No concurrent prescription psychoactive medication
• No history of benzodiazepine dependence
• -Patient Characteristics--
• Age: 18 to 50
• Other: Medically healthy Negative pregnancy test required No occupational requirement to work in hazardous situations